Supernus Pharmaceuticals, Inc. P/E Ratio 2010–2025
Supernus Pharmaceuticals, Inc. reported 27.39 of price-to-earnings ratio for fiscal 2024. That was 98.1% lower than fiscal 2023. Compared with fiscal 2019, the change was +142.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | 27.39 | -98.1% |
| FY 2023 | 1447.00 | +4118.9% |
| FY 2022 | 34.30 | +15.3% |
| FY 2021 | 29.76 | +179.1% |
| FY 2020 | 10.66 | -5.6% |
| FY 2019 | 11.30 | -30.3% |
| FY 2018 | 16.20 | -56.1% |
| FY 2017 | 36.90 | +157.2% |
| FY 2016 | 14.35 | -70.1% |
| FY 2015 | 48.00 | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SUPN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Supernus Pharmaceuticals, Inc. reported 27.39 of price-to-earnings ratio for fiscal 2024. That was 98.1% lower than fiscal 2023. Compared with fiscal 2019, the change was +142.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio?
Supernus Pharmaceuticals, Inc. (SUPN) reported price-to-earnings ratio of 27.39 for fiscal year 2024, per its SEC filings.
How has Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2010 and 2025, SUPN's price-to-earnings ratio declined at roughly 3.7% per year (compound annual rate), from 48.00 to 27.39.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More SUPN financial history
Full SUPN fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →